Merck & Co Inc (MRK): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Merck ( MRK) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1%. By the end of trading, Merck fell $1.42 (-3.3%) to $41.83 on heavy volume. Throughout the day, 37.6 million shares of Merck exchanged hands as compared to its average daily volume of 12.8 million shares. The stock ranged in price between $41.51-$42.75 after having opened the day at $42.24 as compared to the previous trading day's close of $43.25. Other companies within the Drugs industry that declined today were: Echo Therapeutics ( ECTE), down 28.4%, ARCA biopharma ( ABIO), down 24.7%, Keryx Biopharmaceuticals ( KERX), down 21.7%, and Celsion Corporation ( CLSN), down 12.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Merck has a market cap of $132.24 billion and is part of the health care sector. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. Shares are up 6.3% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Merck a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Alimera ( ALIM), up 19.9%, pSivida ( PSDV), up 17.5%, Abaxis ( ABAX), up 14.4%, and Peregrine Pharmaceuticals ( PPHM), up 12.8%, were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts